The Relief study is a randomised, double-blind, placebo-controlled parallel group study. Scientifically, this is considered the gold standard of clinical research. General information about the study is provided below, as well as how to contact us for more information.
People who choose to enrol in the study will be randomly assigned to one of two groups, either receiving tricaprilin or a placebo (inactive substance that looks, tastes and feels like tricaprilin). Neither the study participants nor the doctor running the study will know which of the two groups a participant has been assigned to. This is called “double-blinding” and is important to prevent unintended bias in data collection.
One half of patients will take tricaprilin twice daily. This will be given to participants as a powder to be mixed with 240 mL water and shaken until well blended, similar to how one might drink a protein shake.
The other half of patients will take a placebo twice daily. Again, this is a powder that one mixes with 240 mL water and shakes until well blended.
Once enrolled in the study, participants will complete a diary for 4 weeks to track their migraine attacks prior to receiving the tricaprilin or placebo. They will then receive treatment for 12 weeks and will continue to track their migraine episodes in the diary.
Why use a placebo in this migraine study?
It’s important to gain a clear understanding of the effects of an investigational medication like tricaprilin by testing it against a control group, to see if it works better than a placebo formulation, and has benefit over the psychological effects of thinking one is taking a medication which may help you feel better. You can read more about placebos and why they are so important in science here.